The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.
 
Eliana Rulli
No Relationships to Disclose
 
Mara Serena Serafini
No Relationships to Disclose
 
Mirko Marabese
No Relationships to Disclose
 
Elisa Caiola
No Relationships to Disclose
 
Gabriella Sozzi
No Relationships to Disclose
 
Massimo Moro
No Relationships to Disclose
 
Emilio Bria
No Relationships to Disclose
 
Michele Simbolo
No Relationships to Disclose
 
Adele Busico
No Relationships to Disclose
 
Elena Tamborini
No Relationships to Disclose
 
Giulia Corrao
No Relationships to Disclose
 
Gabriella Farina
No Relationships to Disclose
 
Massimo Broggini
No Relationships to Disclose
 
Monica Ganzinelli
No Relationships to Disclose
 
Marina Chiara Garassino
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Roche
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; MSD Oncology; Pfizer